179 related articles for article (PubMed ID: 19490757)
1. Correlation between flow cytometric identification of CD33-positive cells and morphological evaluation of myeloblasts in bone marrow of patients with acute myeloblastic leukemia.
Oka S; Muroi K; Matsuyama T; Sato K; Ueda M; Toshima M; Suzuki T; Ozaki K; Mori M; Takubo T; Nagai T; Hanafusa T; Ozawa K
Hematology; 2009 Jun; 14(3):133-8. PubMed ID: 19490757
[TBL] [Abstract][Full Text] [Related]
2. A method comparison study of flow cytometry and cytomorphology to determine the percentages of blasts in patients with acute leukemia after induction and consolidation chemotherapy.
Wongprajun S; Auewarakul CU
J Med Assoc Thai; 2010 Jan; 93 Suppl 1():S157-64. PubMed ID: 20364570
[TBL] [Abstract][Full Text] [Related]
3. Flow cytometric detection of residual disease in acute leukemia by assaying blasts co-expressing myeloid and lymphatic antigens.
Syrjälä M; Anttila VJ; Ruutu T; Jansson SE
Leukemia; 1994 Sep; 8(9):1564-70. PubMed ID: 7522295
[TBL] [Abstract][Full Text] [Related]
4. Absence of IL-12Rβ2 in CD33(+)CD38(+) pediatric acute myeloid leukemia cells favours progression in NOD/SCID/IL2RγC-deficient mice.
Ferretti E; Montagna D; Di Carlo E; Cocco C; Ribatti D; Ognio E; Sorrentino C; Lisini D; Bertaina A; Locatelli F; Pistoia V; Airoldi I
Leukemia; 2012 Feb; 26(2):225-35. PubMed ID: 21844875
[TBL] [Abstract][Full Text] [Related]
5. A phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemia.
Kossman SE; Scheinberg DA; Jurcic JG; Jimenez J; Caron PC
Clin Cancer Res; 1999 Oct; 5(10):2748-55. PubMed ID: 10537338
[TBL] [Abstract][Full Text] [Related]
6. Identification of the CD33-related Siglec receptor, Siglec-5 (CD170), as a useful marker in both normal myelopoiesis and acute myeloid leukaemias.
Virgo P; Denning-Kendall PA; Erickson-Miller CL; Singha S; Evely R; Hows JM; Freeman SD
Br J Haematol; 2003 Nov; 123(3):420-30. PubMed ID: 14617000
[TBL] [Abstract][Full Text] [Related]
7. [CD13- and CD33-negative acute myelocytic leukemia (FAB classification; M2) with morphological changes and CD13 expression on recurrence].
Aoyama Y; Yamane T; Kanashima H; Takeoka Y; Koh K; Nakao Y; Yamamura R; Nakamae H; Ohta K; Inoue T; Hino M; Tatsumi N
Rinsho Ketsueki; 2001 Apr; 42(4):314-20. PubMed ID: 11400303
[TBL] [Abstract][Full Text] [Related]
8. Increased myeloid precursors in regenerating bone marrow; implications for detection of minimal residual disease in acute myeloid leukemia.
Zeleznikova T; Stevulova L; Kovarikova A; Babusikova O
Neoplasma; 2007; 54(6):471-7. PubMed ID: 17949229
[TBL] [Abstract][Full Text] [Related]
9. [Screening and structure analysis of nucleic acid aptamers binding to surface of CD33(+)/CD34(+) cells from patients with acute myeloid leukemia subtype M₂].
Zhang SQ; Wang GP; Zhu P; Liang JJ; Xu YJ; Peng MY; Chen Y; Tan SQ; Chen FP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Jun; 19(3):561-5. PubMed ID: 21729522
[TBL] [Abstract][Full Text] [Related]
10. [Multidrug resistance in acute leukemia].
Takeshita A; Ohno R
Rinsho Ketsueki; 1996 Aug; 37(8):640-6. PubMed ID: 8827870
[TBL] [Abstract][Full Text] [Related]
11. Two methods for the quantitative analysis of surface antigen expression in acute myeloid leukemia (AML).
Woźniak J
Folia Histochem Cytobiol; 2004; 42(3):195-9. PubMed ID: 15493582
[TBL] [Abstract][Full Text] [Related]
12. Clinical impact of leukemic blast heterogeneity at diagnosis in cytogenetic intermediate-risk acute myeloid leukemia.
Hoffmann MH; Klausen TW; Boegsted M; Larsen SF; Schmitz A; Leinoe EB; Schmiegelow K; Hasle H; Bergmann OJ; Sorensen S; Nyegaard M; Dybkaer K; Johnsen HE
Cytometry B Clin Cytom; 2012 May; 82(3):123-31. PubMed ID: 22328535
[TBL] [Abstract][Full Text] [Related]
13. Acquisition of CD13 and CD33 expression at relapse on acute myeloid leukemia cells with an unusual phenotype: MPO+CD13-CD33-.
Kawada H; Ichikawa Y; Kobayashi N; Fukuda R; Yonekura S; Nagao T
Intern Med; 1993 Sep; 32(9):733-6. PubMed ID: 7908235
[TBL] [Abstract][Full Text] [Related]
14. TIM3 expression by leukemic and non-leukemic myeloblasts.
Roth CG; Garner K; Eyck ST; Boyiadzis M; Kane LP; Craig FE
Cytometry B Clin Cytom; 2013 May; 84(3):167-72. PubMed ID: 23554257
[TBL] [Abstract][Full Text] [Related]
15. Multiparametric analysis of normal and postchemotherapy bone marrow: Implication for the detection of leukemia-associated immunophenotypes.
Olaru D; Campos L; Flandrin P; Nadal N; Duval A; Chautard S; Guyotat D
Cytometry B Clin Cytom; 2008 Jan; 74(1):17-24. PubMed ID: 18061947
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience.
Plesa C; Chelghoum Y; Plesa A; Elhamri M; Tigaud I; Michallet M; Dumontet C; Thomas X
Cancer; 2008 Feb; 112(3):572-80. PubMed ID: 18085638
[TBL] [Abstract][Full Text] [Related]
17. Leukemia markers expression of peripheral blood vs bone marrow blasts using flow cytometry.
Rezaei A; Adib M; Mokarian F; Tebianian M; Nassiri R
Med Sci Monit; 2003 Aug; 9(8):CR359-62. PubMed ID: 12942032
[TBL] [Abstract][Full Text] [Related]
18. Incidence, sensitivity, and specificity of leukemia-associated phenotypes in acute myeloid leukemia using specific five-color multiparameter flow cytometry.
Al-Mawali A; Gillis D; Hissaria P; Lewis I
Am J Clin Pathol; 2008 Jun; 129(6):934-45. PubMed ID: 18480011
[TBL] [Abstract][Full Text] [Related]
19. Triple immunofluorescence evaluation of CD15, CD34 and class II expression by flow cytometry in normal and leukemic bone marrows.
Venditti A; Del Poeta G; Stasi R; De Fabriitis P; Coppetelli U; Bruno A; Simone MD; Papa G
Haematologica; 1993; 78(6):359-63. PubMed ID: 7513673
[TBL] [Abstract][Full Text] [Related]
20. Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia.
Caron PC; Dumont L; Scheinberg DA
Clin Cancer Res; 1998 Jun; 4(6):1421-8. PubMed ID: 9626458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
